SIRPA and arthritic joint disease: In an experimental arthritis model, SIRPα-Fc reduced arthritis severity by ameliorating joint inflammation via inhibition of neutrophil and monocyte infiltration.51 In line with this, in vivo administration of Miap410, a CD47-blocking antibody, in EAE impaired resolution of CNS inflammation.52 We here show that CD47 is highly expressed in the (NA)GM.